A Phase 4 interventional study of Cyclic Estradiol and Continuous Estradiol in Menopause, Healthy Adult and Brain, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to female participants aged 38 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by University of Colorado, Denver · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn more about how estradiol patch treatment affects brain processes, health, and wellbeing.
University of Colorado, Denver is the lead sponsor of 1,544 studies on the registry; 318 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transdermal estradiol 100 mcg/day patch applied for 5 days every 21 days for approximately 12 weeks.
Drug: Cyclic Estradiol
Transdermal estradiol 100 mcg/day patch worn continuously and replaced every 6 days for approximately 12 weeks.
Drug: Continuous Estradiol
Participants randomized to the cyclic estradiol group apply a transdermal estradiol patch delivering 100 mcg/day for 5 days every 21 days over approximately 12 weeks. The patch is removed on the fifth day of each treatment cycle. The final patch is worn for 7 days.
Also known as: Estradiol Patch, Transdermal Estradiol
Participants randomized to the continuous estradiol group apply a transdermal estradiol patch delivering 100 mcg/day continuously for approximately 12 weeks. The patch is replaced every 6 days and worn throughout the treatment period. The final patch is worn for 7 days.
Also known as: Estradiol Patch, Transdermal Estradiol
Change in Dorsolateral Prefrontal Cortex (dlPFC) activation during working memory task in women receiving either cyclic or continuous estradiol administration.
Description: Dorsolateral prefrontal cortex (dlPFC) activation will be measured during performance of the letter N-back task using functional magnetic resonance imaging (fMRI). Change scores will be calculated from baseline to follow-up.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change from baseline in extracellular vesicle concentration.
Extracellular vesicle (EV) concentration will be measured from plasma samples and reported as particles per milliliter (particles/mL). Changes from baseline will be assessed following cyclic or continuous estradiol administration.
Time frame: Baseline, Days 1-4, Days 21-24, and approximately 12 weeks after treatment initiation
Change from baseline in extracellular vesicle size.
Extracellular vesicle (EV) size will be measured from plasma samples and reported in nanometers (nm). Changes from baseline will be assessed following cyclic or continuous estradiol administration.
Time frame: Baseline, Days 1-4, Days 21-24, and approximately 12 weeks after treatment initiation
Change from baseline in extracellular vesicle zeta potential.
Extracellular vesicle (EV) zeta potential will be measured from plasma samples and reported in millivolts (mV). Changes from baseline will be assessed following cyclic or continuous estradiol administration.
Time frame: Baseline, Days 1-4, Days 21-24, and approximately 12 weeks after treatment initiation
Change in C-reactive protein concentration.
Serum C-reactive protein concentration measured using the Meso Scale Discovery (MSD) V-PLEX Neuroinflammation Panel.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in interleukin concentration.
Interleukin concentration measured using the MSD V-Plex Neuroinflammation Panel.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in cytokine concentration.
Cytokine concentration measured using the MSD V-Plex Neuroinflammation Panel.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in chemokine concentration.
Chemokine concentration measured using the MSD V-Plex Neuroinflammation Panel.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in growth factor concentration.
Growth factor concentration measured using the MSD V-Plex Neuroinflammation Panel.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in executive function symptoms on the Brown Attention-Deficit Disorder Scale (BADDS).
The BADDS is a validated 40-item self-report measure of executive function difficulties. Total scores range from 0 to 120, with higher scores indicating greater executive dysfunction.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in perceived stress on the Perceived Stress Scale (PSS).
The PSS is a 10-item self-report measure of perceived stress. Total scores range from 0 to 40, with higher scores indicating greater perceived stress.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in depressive symptoms on the Center for Epidemiologic Studies Depression Scale (CES-D).
The CES-D is a 20-item self-report measure of depressive symptoms. Total scores range from 0 to 60, with higher scores indicating greater severity of depressive symptoms.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in anxiety symptoms on the Generalized Anxiety Disorder-7 (GAD-7).
The GAD-7 is a 7-item self-report measure of anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Change in hair cortisol concentration.
Hair cortisol concentration is a biomarker of chronic hypothalamic-pituitary-adrenal axis activity. Higher concentrations indicate greater cumulative cortisol exposure over the preceding approximately three months.
Time frame: Baseline and approximately 12 weeks after initiation of study treatment
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol
University of Colorado, Denver →